Table 3B.
Registry survey: RAI patient and control cohort characteristics by center - all age groups.
| Study center | Dept. Nuclear Medicine, University Hospital | Dept. Endocrinology, University Hospital | Dept.Nuclear Medicine & Endocrinology, MSC Memorial Cancer Center | Dept.Nuclear Medicine University Hoispital | ||||
|---|---|---|---|---|---|---|---|---|
| City/country | Münster, Germany | Pisa, Italiy | Gliwice, Poland | Würzburg, Germany | ||||
| N (% of combined study sample) | 1,808 (23.9%) | 1,091 (14.4%) | 867 (11.5%) | 836 (11.1%) | ||||
| Cohorts | RAI patients | Controls* | RAI patients | Controls | RAI patients | Controls | RAI patients | Controls |
| n (% of RAI patient or control cohort) | 1,644 (25.5%) | 164 (14.7%) | 1,091 (16.9%) | 0 | 650 (10.1%) | 217 (19.4%) | 726 (11.3%) | 110 (9.9%) |
| Current age (years, M ± SD) | 56.3 ± 16.2 | 55.5 ± 13.3 | ||||||
| Age at first surgery (years, M ± SD) | 47.6 ± 15.9 | 48.8 ± 13.1 | 44.13 ± 3.0 | 43.3 ± 4.9 | 43.9 ± 2.1 | 45.6 ± 16.1 | 46.7 ± 15.5 | |
| <18 years, n (%) | 44 (6.8%) | 7 (3.2%) | ||||||
| <40 years, n (%) | 241 (37.1%) | 76 (35.0%) | ||||||
| Age at first RAI (years, M ± SD) | 47.8 ± 15.9 | 45.7 ± 16.1 | ||||||
| <18 years, n (%) | 34 (2.1%) | 30 (4.1%) | ||||||
| <40 years, n (%) | 544 (33.1%) | 244 (33.6%) | ||||||
| Cumul. I-131 activity (GBq, M ± SD) | 7.8 ± 10.1 | 6.0 ± 6.5 | 4.0 ± 5.8 | 7.5 ± 6.6 | ||||
| Follow-up duration (years, M ± SD) | 8.6 ± 6.8 | 6.8 ± 6.1 | 16.1 ± 10.4 | 11.4 ± 3.9 | 10.9 ± 4.3 | 4.7 ± 3.72 | 5.74 ± 4.08 | |
| SPM before DTC | ||||||||
| Breast cancer, n (%) | 10 (0.6%) | 3 (1.8%) | 5 (0.5%) | 4 (0.6%) | 0 | 5 (0.7%) | 1 (0.9%) | |
| Other cancers, n (%) | 20 (1.2%) | 1 (0.6%) | 9 (0.8%) | 10 (1.5%) | 0 | 107(14.7%) | 5 (4.5%) | |
| SPM after DTC/RAI | ||||||||
| Breast cancer, n (%) | 16 (1.0%) | 2 (1.2%) | 27 (2.5%) | 11 (1.6%) | 0 | 9 (1.2%) | 2 (1.8%) | |
| Other cancers, n (%) | 13 (0.8%) | 4 (2.4%) | 42 (3.8%) | 14 (2.2%) | 2 (0.9%) | 19 (2.6%) | 4 (3.6%) | |
Cumul., cumulative; Dept., department; DTC, differentiated thyroid carcinoma; I = 131, iodine-131; M ± SD, mean + standard deviation; RAI, radioiodine therapy; SPM, second primary malignancy.
*
Controls were patients with DTC who had not received RAI.